NASDAQ:ALVR AlloVir (ALVR) Stock Price, News & Analysis $0.79 +0.02 (+2.61%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.77▼$0.7950-Day Range$0.70▼$0.8252-Week Range$0.58▼$3.75Volume52,046 shsAverage Volume821,759 shsMarket Capitalization$90.41 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AlloVir alerts: Email Address AlloVir MarketRank™ Stock AnalysisAnalyst RatingReduce1.83 Rating ScoreUpside/Downside2,253.1% Upside$18.50 Price TargetShort InterestHealthy4.93% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.23Based on 10 Articles This WeekInsider TradingSelling Shares$32,004 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.31) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.81 out of 5 starsMedical Sector464th out of 936 stocksBiological Products, Except Diagnostic Industry69th out of 154 stocks 2.9 Analyst's Opinion Consensus RatingAlloVir has received a consensus rating of Reduce. The company's average rating score is 1.83, and is based on 1 buy rating, 3 hold ratings, and 2 sell ratings.Amount of Analyst CoverageAlloVir has received no research coverage in the past 90 days.Read more about AlloVir's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.93% of the outstanding shares of AlloVir have been sold short.Short Interest Ratio / Days to CoverAlloVir has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.Change versus previous monthShort interest in AlloVir has recently decreased by 6.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlloVir does not currently pay a dividend.Dividend GrowthAlloVir does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALVR. Previous Next 1.5 News and Social Media Coverage News SentimentAlloVir has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for AlloVir this week, compared to 2 articles on an average week.Search Interest2 people have searched for ALVR on MarketBeat in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AlloVir insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,004.00 in company stock.Percentage Held by Insiders33.85% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of AlloVir is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AlloVir's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AlloVir are expected to grow in the coming year, from ($0.31) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AlloVir is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AlloVir is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlloVir has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about AlloVir's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHeard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About AlloVir Stock (NASDAQ:ALVR)Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.Read More ALVR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALVR Stock News HeadlinesMay 14, 2024 | investorplace.comALVR Stock Earnings: AlloVir Misses EPS for Q1 2024May 1, 2024 | finance.yahoo.comAlloVir, Inc. (ALVR)July 27, 2024 | DTI (Ad)How to build the ultimate dividend portfolioThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again.March 21, 2024 | stockhouse.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMarch 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVRMarch 19, 2024 | stockhouse.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMarch 18, 2024 | investorplace.comALVR Stock Earnings: AlloVir Misses EPS for Q4 2023March 17, 2024 | businesswire.comALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities ...July 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.March 17, 2024 | businesswire.comALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVRMarch 15, 2024 | stockhouse.com4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the FirmMarch 15, 2024 | prnewswire.comALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMarch 14, 2024 | prnewswire.comClass Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law FirmMarch 14, 2024 | stockhouse.com5-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the FirmMarch 12, 2024 | prnewswire.comALVR IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVRMarch 12, 2024 | prnewswire.comAlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVRMarch 11, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMarch 9, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirSee More Headlines Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/27/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALVR CUSIPN/A CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$20.00 Low Stock Price Target$17.00 Potential Upside/Downside+2,253.1%Consensus RatingReduce Rating Score (0-4)1.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-98.50% Return on Assets-78.56% Debt Debt-to-Equity RatioN/A Current Ratio18.48 Quick Ratio18.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book0.61Miscellaneous Outstanding Shares115,000,000Free Float76,074,000Market Cap$90.41 million OptionableOptionable Beta0.78 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. David L. Hallal (Age 58)Executive Chairman of the Board Comp: $254.38kDr. Diana M. Brainard M.D. (Age 52)CEO & Director Comp: $978.99kMr. Vikas Sinha C.A. (Age 61)CPA, M.B.A., President, CFO & Director Comp: $536.21kMr. Edward Miller J.D. (Age 59)General Counsel & Secretary Comp: $618.39kMr. Brett R. Hagen (Age 51)Chief Accounting Officer Mr. Dana M. Alexander (Age 48)Senior Vice President of Technical Operations Dr. Ann M. Leen Ph.D. (Age 46)Chief Scientific Officer Mr. Ugo Capolino PerlingieriHead & GM of Europe and Middle East OperationsMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer More ExecutivesKey CompetitorsAtara BiotherapeuticsNASDAQ:ATRAbluebird bioNASDAQ:BLUESolid BiosciencesNASDAQ:SLDBALX OncologyNASDAQ:ALXOKamadaNASDAQ:KMDAView All CompetitorsInsiders & InstitutionsVikas SinhaSold 1,858 sharesTotal: $1,374.92 ($0.74/share)Edward MillerSold 757 sharesTotal: $560.18 ($0.74/share)Brett R HagenSold 481 sharesTotal: $355.94 ($0.74/share)Vikas SinhaSold 1,542 sharesTotal: $1,156.50 ($0.75/share)Diana BrainardSold 9,731 sharesTotal: $7,298.25 ($0.75/share)View All Insider TransactionsView All Institutional Transactions ALVR Stock Analysis - Frequently Asked Questions How have ALVR shares performed this year? AlloVir's stock was trading at $0.6798 at the beginning of 2024. Since then, ALVR stock has increased by 15.7% and is now trading at $0.7862. View the best growth stocks for 2024 here. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) released its earnings results on Monday, May, 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.02. When did AlloVir IPO? AlloVir (ALVR) raised $252 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are AlloVir's major shareholders? Top institutional investors of AlloVir include Concourse Financial Group Securities Inc.. Insiders that own company stock include Gilead Sciences, Inc, Diana Brainard, Beek Jeroen B Van, Edward Miller, David Hallal, Brett R Hagen, Jeffrey S Bornstein, Morana Jovan-Embiricos, Ercem Atillasoy, Ann M Leen and Agustin Melian. View institutional ownership trends. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT) and Boeing (BA). This page (NASDAQ:ALVR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.